Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 CAR-NK Cells for Refractory/Relapsed SLE
NCT06421701Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Anti-CD19 CAR-NK cells in systemic lupus erythematosus (SLE), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Proportion of subjects with adverse events at 12 months. Started Aug 2024; status: recruiting.
02
Drugs
Anti-CD19 CAR-NK cells
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06421701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06421701.